cas 884494-34-2|| where to buy 2-ethynyl-5-fluoropyridine

Produktname:2-ethynyl-5-fluoropyridine

IUPAC Name:2-ethynyl-5-fluoropyridine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM171185-1g	in stock	ĳǟƚ
CM171185-5g	in stock	ħŌŌ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 884494-34-2 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:884494-34-2; Molekulare Formel:C7H4FN; Schmelzpunkt:-; SMILES-Code:FC1=CN=C(C#C)C=C1; Dichte:

: Katalognummer:CM171185; Molekulargewicht:121.11; Siedepunkt:150.6°C at 760 mmHg; Mdl-Nr.:MFCD03095259; Lagerung:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Olutasidenib; Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.